title: Dose delivered from Varian's CBCT to patients receiving IMRT for prostate cancer.
abstract: With the increased use of cone beam CT (CBCT) for daily patient setup, the accumulated dose from CBCT may be significantly higher than that from simulation CT or portal imaging. The objective of this work is to measure the dose from daily pelvic scans with fixed technical settings and collimations. CBCT scans were acquired in half-fan mode using a half bowtie and x-rays were delivered in pulsed-fluoro mode. The skin doses for seven prostate patients were measured on an IRB-approved protocol. TLD capsules were placed on the patient's skin at the central axis of three beams: AP, left lateral (Lt Lat) and right lateral (Rt Lat). To avoid the ring artefacts centred in the prostate, the treatment couch was dropped 3 cm from the patient's tattoo (central axis). The measured AP skin doses ranged 3-6 cGy for 20-33 cm separation. The larger the patient size the less the AP skin dose. Lateral doses did not change much with patient size. The Lt Lat dose was approximately 4.0 cGy, which was approximately 40% higher than the Rt Lat dose of approximately 2.6 cGy. To verify this dose asymmetry, surface doses on an IMRT QA phantom (oval shaped, 30 cm x 20 cm) were measured at the same three sites using TLD capsules with 3 cm table-drop. The dose asymmetry was due to: (1) kV source rotation which always starts from the patient's Lt Lat and ends at Lt Lat. Gantry rotation gets much slower near the end of rotation but dose rate stays constant and (2) 370 degrees scan rotation (10 degrees scan overlap on the Lt Lat side). In vivo doses were measured inside a Rando pelvic heterogeneous phantom using TLDs. The left hip (femoral head and neck) received the highest doses of approximately 10-11 cGy while the right hip received approximately 6-7 cGy. The surface and in vivo doses were also measured for phantoms at the central-axis setup. The difference was less than approximately 12% to the table-drop setup.
authors.affiliation: Henry Ford Health System, Detroit, MI, USA.
authors.forename: Ning
authors.initials: N
authors.lastname: Wen
authors.forename: Huaiqun
authors.initials: H
authors.lastname: Guan
authors.forename: Rabih
authors.initials: R
authors.lastname: Hammoud
authors.forename: Deepak
authors.initials: D
authors.lastname: Pradhan
authors.forename: T
authors.initials: T
authors.lastname: Nurushev
authors.forename: Shidong
authors.initials: S
authors.lastname: Li
authors.forename: Benjamin
authors.initials: B
authors.lastname: Movsas
mesh_terms: D001822:Body Burden; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D011829:Radiation Dosage; D020266:Radiotherapy, Conformal / Q000379:methods*; D012062:Relative Biological Effectiveness; D018570:Risk Assessment; D012307:Risk Factors; D013819:Thermoluminescent Dosimetry; D036542:Tomography, Spiral Computed / Q000379:methods*